Luye Pharma Group Ltd (LUP) - Total Assets
Based on the latest financial reports, Luye Pharma Group Ltd (LUP) holds total assets worth €32.83 Billion EUR (≈ $38.38 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Luye Pharma Group Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Luye Pharma Group Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Luye Pharma Group Ltd's total assets have evolved over time, based on quarterly financial data. See what is Luye Pharma Group Ltd's book value for net asset value and shareholders' equity analysis.
Luye Pharma Group Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Luye Pharma Group Ltd's total assets of €32.83 Billion consist of 46.4% current assets and 53.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.7% |
| Accounts Receivable | €2.85 Billion | 8.7% |
| Inventory | €956.54 Million | 2.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.78 Billion | 20.7% |
| Goodwill | €1.08 Billion | 3.3% |
Asset Composition Trend (2016–2025)
This chart illustrates how Luye Pharma Group Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LUP market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Luye Pharma Group Ltd's current assets represent 46.4% of total assets in 2025, a decrease from 57.4% in 2016.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2025, up from 4.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 19.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 20.7% of total assets.
Luye Pharma Group Ltd Competitors by Total Assets
Key competitors of Luye Pharma Group Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Luye Pharma Group Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.53 | 1.24 | 1.38 |
| Quick Ratio | 1.44 | 1.15 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.30 Billion | €2.54 Billion | €2.74 Billion |
Luye Pharma Group Ltd - Advanced Valuation Insights
This section examines the relationship between Luye Pharma Group Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 10.9% |
| Total Assets | €32.83 Billion |
| Market Capitalization | $1.05 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Luye Pharma Group Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Luye Pharma Group Ltd's assets grew by 10.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Luye Pharma Group Ltd (2016–2025)
The table below shows the annual total assets of Luye Pharma Group Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €32.83 Billion ≈ $38.38 Billion |
+10.85% |
| 2024-12-31 | €29.61 Billion ≈ $34.62 Billion |
+16.17% |
| 2023-12-31 | €25.49 Billion ≈ $29.80 Billion |
+5.12% |
| 2022-12-31 | €24.25 Billion ≈ $28.35 Billion |
+7.38% |
| 2021-12-31 | €22.58 Billion ≈ $26.40 Billion |
+9.46% |
| 2020-12-31 | €20.63 Billion ≈ $24.12 Billion |
+6.82% |
| 2019-12-31 | €19.31 Billion ≈ $22.58 Billion |
+10.12% |
| 2018-12-31 | €17.54 Billion ≈ $20.50 Billion |
+62.99% |
| 2017-12-31 | €10.76 Billion ≈ $12.58 Billion |
+16.89% |
| 2016-12-31 | €9.21 Billion ≈ $10.76 Billion |
-- |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more